tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2022 May 23.
doi: 10.1080/14760584.2022.2081156. Online ahead of print.
The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?
Amresh Kumar[SUP] 1 [/SUP], Amit Ladha[SUP] 2 [/SUP], Ankita Choudhury[SUP] 3 [/SUP], Abu Md Ashif Ikbal[SUP] 4 [/SUP], Bedanta Bhattacharjee[SUP] 5 [/SUP], Tanmay Das[SUP] 6 [/SUP], Gaurav Gupta[SUP] 2 7 [/SUP], Chhavi Sharma[SUP] 2 [/SUP], Adity Sarbajna[SUP] 8 [/SUP], Subhash C Mandal[SUP] 9 [/SUP], Manabendra Dutta Choudhury[SUP] 1 [/SUP], Nahid Ali[SUP] 10 [/SUP], Petr Slama[SUP] 11 [/SUP], Nima Rezaei[SUP] 12 13 14 [/SUP], Partha Palit[SUP] 15 [/SUP], Onkar Nath Tiwari[SUP] 16 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as one of the biggest global health issues. Spike protein (S) and nucleoprotein (N), the major immunogenic components of SARS-CoV-2, have been shown to be involved in the attachment and replication of the virus inside the host cell.
Areas covered: Several investigations have shown that the SARS-CoV-2 nucleoprotein can elicit a cell-mediated immune response capable of regulating viral replication and lowering viral burden. However, development of an effective vaccine that can stop the transmission of SARS-CoV-2 remains a matter of concern. Literature was retrieved using the key words COVID-19 vaccine, role of nucleoprotein as vaccine candidate, spike protein, nucleoprotein immune responses against SARS-CoV-2, and chimera vaccine in PubMed, Google Scholar, and Google.
Expert opinion: We have focused on the use of chimera protein, consisting of N and S-1 protein components of SARS-CoV-2, as a potential vaccine candidate. This may act as polyvalent mixed recombinant protein vaccine to elicit strong T and B cell immune response, which will be capable of neutralizing the wild and mutated variants of SARS-CoV-2, and also restricting its attachment, replication, and budding in the host cell.
Keywords: B cells; COVID-19; S-1 and N proteins; T cells; antibody; chimeric recombinant protein mixture; mutated variant of SARS-CoV-2; vaccine candidate.
. 2022 May 23.
doi: 10.1080/14760584.2022.2081156. Online ahead of print.
The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?
Amresh Kumar[SUP] 1 [/SUP], Amit Ladha[SUP] 2 [/SUP], Ankita Choudhury[SUP] 3 [/SUP], Abu Md Ashif Ikbal[SUP] 4 [/SUP], Bedanta Bhattacharjee[SUP] 5 [/SUP], Tanmay Das[SUP] 6 [/SUP], Gaurav Gupta[SUP] 2 7 [/SUP], Chhavi Sharma[SUP] 2 [/SUP], Adity Sarbajna[SUP] 8 [/SUP], Subhash C Mandal[SUP] 9 [/SUP], Manabendra Dutta Choudhury[SUP] 1 [/SUP], Nahid Ali[SUP] 10 [/SUP], Petr Slama[SUP] 11 [/SUP], Nima Rezaei[SUP] 12 13 14 [/SUP], Partha Palit[SUP] 15 [/SUP], Onkar Nath Tiwari[SUP] 16 [/SUP]
Affiliations
- PMID: 35604776
- DOI: 10.1080/14760584.2022.2081156
Abstract
Introduction: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as one of the biggest global health issues. Spike protein (S) and nucleoprotein (N), the major immunogenic components of SARS-CoV-2, have been shown to be involved in the attachment and replication of the virus inside the host cell.
Areas covered: Several investigations have shown that the SARS-CoV-2 nucleoprotein can elicit a cell-mediated immune response capable of regulating viral replication and lowering viral burden. However, development of an effective vaccine that can stop the transmission of SARS-CoV-2 remains a matter of concern. Literature was retrieved using the key words COVID-19 vaccine, role of nucleoprotein as vaccine candidate, spike protein, nucleoprotein immune responses against SARS-CoV-2, and chimera vaccine in PubMed, Google Scholar, and Google.
Expert opinion: We have focused on the use of chimera protein, consisting of N and S-1 protein components of SARS-CoV-2, as a potential vaccine candidate. This may act as polyvalent mixed recombinant protein vaccine to elicit strong T and B cell immune response, which will be capable of neutralizing the wild and mutated variants of SARS-CoV-2, and also restricting its attachment, replication, and budding in the host cell.
Keywords: B cells; COVID-19; S-1 and N proteins; T cells; antibody; chimeric recombinant protein mixture; mutated variant of SARS-CoV-2; vaccine candidate.